|
US4133814A
(en)
|
1975-10-28 |
1979-01-09 |
Eli Lilly And Company |
2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
|
|
US4418068A
(en)
|
1981-04-03 |
1983-11-29 |
Eli Lilly And Company |
Antiestrogenic and antiandrugenic benzothiophenes
|
|
GB8327256D0
(en)
|
1983-10-12 |
1983-11-16 |
Ici Plc |
Steroid derivatives
|
|
DE4126999A1
(de)
|
1991-08-16 |
1993-02-18 |
Basf Ag |
Herbizide mittel, enthaltend 3-aminobenzo(b)thiophene als antidots
|
|
EP0545478A1
(en)
|
1991-12-03 |
1993-06-09 |
MERCK SHARP & DOHME LTD. |
Heterocyclic compounds as tachykinin antagonists
|
|
CZ285937B6
(cs)
|
1992-01-16 |
1999-12-15 |
Hoechst Aktiengesellschaft |
Arylcykloalkylové deriváty, způsob přípravy těchto derivátů a jejich použití
|
|
TW366342B
(en)
|
1992-07-28 |
1999-08-11 |
Lilly Co Eli |
The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
|
|
EP0622673B1
(en)
|
1993-04-24 |
1998-02-04 |
Kodak Limited |
Photographic colour couplers and photographic materials containing them
|
|
US5478847A
(en)
|
1994-03-02 |
1995-12-26 |
Eli Lilly And Company |
Methods of use for inhibiting bone loss and lowering serum cholesterol
|
|
EP0752421B1
(en)
|
1995-07-07 |
2005-10-12 |
AstraZeneca AB |
Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
|
|
US6458811B1
(en)
|
1996-03-26 |
2002-10-01 |
Eli Lilly And Company |
Benzothiophenes formulations containing same and methods
|
|
US5998402A
(en)
|
1996-04-19 |
1999-12-07 |
American Home Products Corporation |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
|
|
TW397821B
(en)
|
1996-04-19 |
2000-07-11 |
American Home Produits Corp |
3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
|
|
US5880137A
(en)
|
1996-04-19 |
1999-03-09 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
US5780497A
(en)
|
1996-04-19 |
1998-07-14 |
American Home Products Corporation |
2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
|
|
ES2301194T3
(es)
|
1997-02-05 |
2008-06-16 |
Warner-Lambert Company Llc |
Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
JP2001519349A
(ja)
|
1997-10-03 |
2001-10-23 |
イーライ・リリー・アンド・カンパニー |
ベンゾチオフェン
|
|
US6005102A
(en)
|
1997-10-15 |
1999-12-21 |
American Home Products Corporation |
Aryloxy-alkyl-dialkylamines
|
|
ID24568A
(id)
|
1997-11-06 |
2000-07-27 |
American Home Prod |
Kontrasepsi oral yang mengandung anti-estrogen plus progestin
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
US6479535B1
(en)
|
1998-05-15 |
2002-11-12 |
Wyeth |
2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
|
|
US6583170B1
(en)
|
1998-05-15 |
2003-06-24 |
Wyeth |
2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
US7091240B2
(en)
|
2000-03-10 |
2006-08-15 |
Oxigene, Inc. |
Tubulin binding ligands and corresponding prodrug constructs
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
IL152771A0
(en)
|
2000-06-26 |
2003-06-24 |
Pfizer Prod Inc |
PYRROLO(2,3-d) PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
|
|
AR030064A1
(es)
|
2000-07-06 |
2003-08-13 |
Wyeth Corp |
Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
|
|
AU2001271784A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Therapy for prosthesis-related bone degeneration
|
|
AU2001271782A1
(en)
|
2000-07-06 |
2002-01-21 |
Wyeth |
Use of substituted insole compounds for treating excessive intraocular pressure
|
|
JP2004502731A
(ja)
|
2000-07-06 |
2004-01-29 |
ワイス |
スタチン、エストロゲン剤および所望によるエストロゲンの組み合わせ
|
|
MXPA02012897A
(es)
|
2000-07-06 |
2003-10-24 |
Wyeth Corp |
Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos.
|
|
US6358991B2
(en)
|
2000-07-06 |
2002-03-19 |
American Home Products Corporation |
Methods of treating neuropeptide Y-related conditions
|
|
WO2002003989A2
(en)
|
2000-07-06 |
2002-01-17 |
Wyeth |
Use of substituted indole compounds for treating sphincter incontinence
|
|
US20020016318A1
(en)
|
2000-07-06 |
2002-02-07 |
American Home Products Corporation |
Methods of treating breast disorders
|
|
EP1990051A1
(en)
|
2000-07-06 |
2008-11-12 |
Wyeth |
Combinations of SSRI and estrogenic agents
|
|
MXPA02012890A
(es)
|
2000-07-06 |
2003-10-24 |
Wyeth Corp |
Uso de compuestos de indol sustituidos para incrementar la actividad de oxido nitrico sintasa.
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
ES2251677T3
(es)
|
2002-01-22 |
2006-05-01 |
Warner-Lambert Company Llc |
2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
|
|
EP1527076B1
(en)
|
2002-07-24 |
2005-12-28 |
Eli Lilly And Company |
Dihydro-dibenzo[b,e]oxepine based selective estrogen receptor modulators, compositions and methods
|
|
EP1590341B1
(en)
|
2003-01-17 |
2009-06-17 |
Warner-Lambert Company LLC |
2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
|
|
ATE412650T1
(de)
|
2003-07-11 |
2008-11-15 |
Warner Lambert Co |
Isethionat salz eines selektiven cdk4 inhibitors
|
|
JP2007502307A
(ja)
|
2003-08-15 |
2007-02-08 |
アストラゼネカ アクチボラグ |
グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
|
|
KR100798161B1
(ko)
|
2003-10-23 |
2008-01-28 |
에프. 호프만-라 로슈 아게 |
신경병적 또는 신경정신병적 장애의 치료에서 ｇｌｙｔ-1저해제로서 사용하기 위한 트라이아자-스피로피페리딘유도체
|
|
JP2005129430A
(ja)
|
2003-10-27 |
2005-05-19 |
Konica Minolta Holdings Inc |
光電変換材料用半導体、光電変換素子及び太陽電池
|
|
FR2862646B1
(fr)
|
2003-11-20 |
2006-02-24 |
Merck Sante Sas |
Nouveaux composes antidiabetiques contenant des derives benzofuranes, benzothiophenes
|
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
|
BRPI0417407A
(pt)
|
2003-12-15 |
2007-04-03 |
Theramex |
derivados de 1-n-fenil-amino-1h-imidazol e composições farmacêuticas contendo estes
|
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
|
EP1846408B1
(en)
|
2005-01-14 |
2013-03-20 |
Janssen Pharmaceutica NV |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
|
CA2595477A1
(en)
|
2005-01-21 |
2006-07-27 |
Janssen Pharmaceutica N.V. |
Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
|
US8278290B2
(en)
|
2005-02-14 |
2012-10-02 |
Biononics Limited |
Tubulin polymerisation inhibitors
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
AU2007211840B2
(en)
|
2006-02-03 |
2012-03-01 |
Bionomics Limited |
Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
|
|
CA2656067C
(en)
|
2006-06-23 |
2014-08-12 |
Radius Health, Inc. |
Treatment of vasomotor symptoms with selective estrogen receptor modulators
|
|
EP1947085A1
(en)
|
2007-01-19 |
2008-07-23 |
Laboratorios del Dr. Esteve S.A. |
Substituted indole sulfonamide compounds, their preparation and use as medicaments
|
|
JP2010531364A
(ja)
|
2007-06-25 |
2010-09-24 |
ニューロジェン・コーポレーション |
ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体
|
|
EP2183237A1
(en)
|
2007-07-25 |
2010-05-12 |
F. Hoffmann-Roche AG |
Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators
|
|
US9259399B2
(en)
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
BRPI0821209A2
(pt)
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
|
EP2320903B1
(en)
|
2008-07-29 |
2017-01-18 |
Nerviano Medical Sciences S.r.l. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
JP2012504646A
(ja)
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
|
|
CN102231983A
(zh)
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
|
WO2010075542A1
(en)
|
2008-12-23 |
2010-07-01 |
Curis, Inc. |
Cdk inhibitors
|
|
WO2010093578A1
(en)
|
2009-02-10 |
2010-08-19 |
Glaxo Group Limited |
Indolinyl-, benzofuranyl-, and benzothienyl- amides as modulators of chemokine receptors
|
|
WO2010127452A1
(en)
|
2009-05-04 |
2010-11-11 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
5-oxo-ete receptor antagonist compounds
|
|
EP3406260B1
(en)
|
2009-05-13 |
2020-09-23 |
The University of North Carolina at Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2011103485A1
(en)
|
2010-02-18 |
2011-08-25 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
BR112012027745A2
(pt)
|
2010-04-27 |
2017-01-10 |
Univ Johns Hopkins |
método e composição imunogênica para tratamento de neoplásia
|
|
HUE033581T2
(hu)
|
2010-06-10 |
2017-12-28 |
Seragon Pharmaceuticals Inc |
Ösztrogén receptor modulátorok és alkalmazásaik
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
US8642632B2
(en)
|
2010-07-02 |
2014-02-04 |
Radius Health, Inc. |
Selective androgen receptor modulators
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
US10005750B2
(en)
|
2010-10-06 |
2018-06-26 |
J-Pharma Co., Ltd. |
Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
KR102051881B1
(ko)
|
2010-10-25 |
2019-12-04 |
쥐원 쎄라퓨틱스, 인크. |
Cdk 억제제
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
JP6112625B2
(ja)
|
2011-12-14 |
2017-04-12 |
セラゴン ファーマシューティカルズ，インク． |
フッ素化したエストロゲン受容体モジュレーターおよびその使用
|
|
PE20150099A1
(es)
|
2011-12-16 |
2015-01-30 |
Olema Pharmaceuticals Inc |
Compuestos novedosos de benzopirano, composiciones y usos de los mismos
|
|
JP2015505562A
(ja)
|
2012-01-31 |
2015-02-23 |
ノバルティス アーゲー |
Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
|
|
SG11201405918XA
(en)
|
2012-03-20 |
2014-10-30 |
Seragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
EP2841417A1
(en)
|
2012-04-26 |
2015-03-04 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
CN104583099A
(zh)
|
2012-09-05 |
2015-04-29 |
皇家飞利浦有限公司 |
用于饮料的制备的胶囊、设备和方法
|
|
EP2912033A4
(en)
|
2012-10-24 |
2016-09-14 |
Univ Illinois |
COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-MEDIATED ILLNESSES
|
|
WO2014066692A1
(en)
|
2012-10-24 |
2014-05-01 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods for treating estrogen-related medical disorders
|
|
BR112015018882B1
(pt)
|
2013-02-19 |
2021-09-14 |
Novartis Ag |
Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
|
|
JP2016517420A
(ja)
|
2013-03-14 |
2016-06-16 |
セラゴン ファーマシューティカルズ， インク． |
多環式エストロゲン受容体モジュレーター及びその使用
|
|
HK1222766A1
(zh)
|
2013-03-15 |
2017-07-14 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
DK2968290T3
(da)
|
2013-03-15 |
2019-11-25 |
G1 Therapeutics Inc |
Transient beskyttelse af normale celler under kemoterapi
|
|
WO2014144596A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
TWI653235B
(zh)
|
2013-05-28 |
2019-03-11 |
阿斯特捷利康公司 |
作為抗癌劑之吲哚衍生物
|
|
EA031077B1
(ru)
|
2013-06-19 |
2018-11-30 |
Серагон Фармасьютикалз, Инк. |
Модулятор рецептора эстрогена и его применения
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
|
BR112015030595A2
(pt)
|
2013-06-19 |
2017-07-25 |
Seragon Pharmaceuticals Inc |
moduladores de receptor de estrogênio de azetidina e usos dos mesmos
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2015028409A1
(de)
|
2013-08-27 |
2015-03-05 |
Bayer Pharma Aktiengesellschaft |
6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
US20160257688A1
(en)
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
CA2941161A1
(en)
|
2014-03-13 |
2015-09-17 |
F.Hoffmann-La Roche Ag |
Methods and compositions for modulating estrogen receptor mutants
|
|
JP2017507964A
(ja)
|
2014-03-13 |
2017-03-23 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
エストロゲン受容体モジュレーターを用いた治療的組合せ
|
|
FI3834824T3
(fi)
|
2014-03-28 |
2025-12-05 |
Univ Duke |
Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
|
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
US20160020862A1
(en)
*
|
2014-07-17 |
2016-01-21 |
Qualcomm Incorporated |
Impedance tuning for a power amplifier load tuner, a receive tuner, and an antenna tuner
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
CN107406424B
(zh)
|
2014-12-18 |
2020-08-25 |
豪夫迈·罗氏有限公司 |
雌激素受体调节剂及其用途
|
|
KR102785474B1
(ko)
|
2014-12-18 |
2025-03-26 |
에프. 호프만-라 로슈 아게 |
테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
|
|
EP3233818A1
(en)
|
2014-12-18 |
2017-10-25 |
F. Hoffmann-La Roche AG |
Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
|
|
WO2016174551A1
(en)
|
2015-04-27 |
2016-11-03 |
Pfizer Inc. |
Anti-estrogenic compounds
|
|
EP3303326B1
(en)
|
2015-05-26 |
2020-12-16 |
H. Hoffnabb-La Roche Ag |
Heterocyclic estrogen receptor modulators and uses thereof
|
|
KR20180012853A
(ko)
|
2015-06-16 |
2018-02-06 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
|
|
KR102710603B1
(ko)
|
2015-10-01 |
2024-09-27 |
올레마 파마슈티컬스 인코포레이티드 |
테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
|
|
WO2017056115A1
(en)
|
2015-10-03 |
2017-04-06 |
Sun Pharma Advanced Research Company Limited |
Novel n-aryl containing fused heterocyclic compounds
|
|
US9975856B2
(en)
|
2015-10-07 |
2018-05-22 |
Genentech, Inc. |
Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
|
|
MX385940B
(es)
|
2015-10-27 |
2025-03-18 |
Sun Pharma Advanced Res Co Ltd |
Nuevos antiestrógenos heterocíclicos.
|
|
US10399939B2
(en)
|
2015-11-09 |
2019-09-03 |
Genentech, Inc. |
Tetrahydronaphthalene estrogen receptor modulators and uses thereof
|
|
US10519148B2
(en)
|
2015-11-12 |
2019-12-31 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Acrylic acid derivative, preparation method and use in medicine thereof
|
|
SMT202300018T1
(it)
|
2015-12-09 |
2023-03-17 |
Univ Illinois |
Downregolatori del recettore degli estrogeni a base di benzotiofene
|
|
JP7106462B2
(ja)
|
2016-07-01 |
2022-07-26 |
ジー１ セラピューティクス， インコーポレイテッド |
Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
EP3858835A1
(en)
|
2016-07-01 |
2021-08-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
IL303038B2
(en)
|
2016-12-05 |
2024-08-01 |
G1 Therapeutics Inc |
Preservation of immune response during chemotherapy regimens
|
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
|
KR20190117582A
(ko)
|
2017-02-10 |
2019-10-16 |
쥐원 쎄라퓨틱스, 인크. |
벤조티오펜 에스트로겐 수용체 조정제
|
|
FI3645001T3
(fi)
|
2017-06-29 |
2024-09-25 |
G1 Therapeutics Inc |
Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
|
|
WO2019136244A1
(en)
|
2018-01-04 |
2019-07-11 |
G1 Therapeutics, Inc. |
Heterocyclic compounds for the treatment of abnormal cellular proliferation
|
|
MX2020007312A
(es)
|
2018-01-08 |
2021-01-08 |
G1 Therapeutics Inc |
Regimenes de dosificacion superior de g1t38.
|
|
CN112218634A
(zh)
|
2018-04-09 |
2021-01-12 |
G1治疗公司 |
具有驱动致癌突变的癌症的治疗
|
|
CN112839646A
(zh)
|
2018-08-16 |
2021-05-25 |
G1治疗公司 |
用于治疗医学疾病的苯并噻吩雌激素受体调节剂
|
|
RS67557B1
(sr)
|
2018-08-24 |
2026-01-30 |
Pharmacosmos Holding As |
Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona
|
|
JP2022506829A
(ja)
|
2018-11-09 |
2022-01-17 |
ジー１、セラピューティクス、インコーポレイテッド |
エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|